Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.
Shaohong LuoShufei LaiYajing WuJinsheng HongDong LinShen LinXiaoting HuangXiongwei XuXiuhua WengPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2024)
Compared with corticosteroids, bevacizumab is an economical option for CRN treatment in China.